scholarly journals CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

2011 ◽  
Vol 11 (3) ◽  
pp. 670-679 ◽  
Author(s):  
Mangeng Cheng ◽  
Matthew R. Quail ◽  
Diane E. Gingrich ◽  
Gregory R. Ott ◽  
Lihui Lu ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Anaplastic Lymphoma Kinase ◽  
Experimental Models ◽  
Active Inhibitor ◽  
Anaplastic Lymphoma ◽  
Human Cancers ◽  
Orally Active

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

2016 ◽  
Vol 59 (10) ◽  
pp. 4948-4964 ◽  
Author(s):  
Wei-Sheng Huang ◽  
Shuangying Liu ◽  
Dong Zou ◽  
Mathew Thomas ◽  
Yihan Wang ◽  
...  
Keyword(s):  
Phosphine Oxide ◽  
Anaplastic Lymphoma Kinase ◽  
Active Inhibitor ◽  
Anaplastic Lymphoma ◽  
Orally Active

scholarly journals Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity

2010 ◽  
Vol 1 (9) ◽  
pp. 493-498 ◽  
Author(s):  
Gregory R. Ott ◽  
Rabindranath Tripathy ◽  
Mangeng Cheng ◽  
Robert McHugh ◽  
Andrew V. Anzalone ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Anaplastic Lymphoma Kinase ◽  
Potent Inhibitor ◽  
Anaplastic Lymphoma ◽  
In Vivo Antitumor Activity
Sign in / Sign up

Export Citation Format

Share Document